Association of IL28B Genotypes with Metabolic Profiles and Viral Clearance Rate in Chronic Hepatitis C Patients

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2015 Jul 24

PMID 26201631

Citations 3

Authors

Ching-Sheng Hsu

Shih-Jer Hsu

Hung-Chia Chen

Chen-Hua Liu

Jenher Jeng

Chun-Jen Liu

Pei-Jer Chen

Ding-Shinn Chen

Jia-Horng Kao

Affiliations

Soon will be listed here.

Abstract

Purpose: IL28B genotypes have a strong impact on treatment outcomes of chronic hepatitis C (CHC) and on-treatment viral kinetics. Since metabolic regulation and interferon response are highly integrated, metabolic profiles may play an important role in the link between IL28B genotypes and hepatitis C virus (HCV) infection. Thus, the association of IL28B rs8099917 genotypes with metabolic profiles and the impact of metabolic profiles on hepatitis C viral kinetic parameters were examined.

Methods: A case-control analysis including 278 CHC patients and 280 subjects without chronic HCV infection was performed. The associations of IL28B rs8099917 genotype with pretreatment metabolic profiles and early viral kinetic parameters were evaluated.

Results: Compared to HCV genotype 1 patients, the differences in metabolic profiles were more significant in genotype 2 patients. HCV genotype 2 patients with TT genotype had higher serum total cholesterol and high density lipoprotein (HDL) levels than those with GT genotype, and the differences remained significant when adjusted for age, sex, and body mass index (p = 0.005 for total cholesterol; p = 0.006 for HDL). In addition, patients with higher serum TG, higher fasting blood glucose, and lower HDL had a lower viral clearance rate.

Conclusions: IL28B genotypes may affect lipid profiles of CHC patients, especially in HCV-genotype 2 patients. Patients with higher serum fasting blood glucose, triglyceride, and lower HDL have a lower viral clearance rate during pegylated interferon plus ribavirin therapy.

Citing Articles

Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.

Hsu C, Hsu S, Liu W, Chen D, Kao J Sci Rep. 2016; 6:32303.

PMID: 27561198 PMC: 4999819. DOI: 10.1038/srep32303.

Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico.

Gonzalez-Aldaco K, Rebello Pinho J, Roman S, Gleyzer K, Fierro N, Oyakawa L PLoS One. 2016; 11(1):e0146258.

PMID: 26741362 PMC: 4704808. DOI: 10.1371/journal.pone.0146258.

Immunologic, metabolic and genetic factors in hepatitis C virus infection.

Fierro N, Gonzalez-Aldaco K, Torres-Valadez R, Martinez-Lopez E, Roman S, Panduro A World J Gastroenterol. 2014; 20(13):3443-56.

PMID: 24707127 PMC: 3974511. DOI: 10.3748/wjg.v20.i13.3443.

References

Harrison S, Rossaro L, Hu K, Patel K, Tillmann H, Dhaliwal S . Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010; 52(3):864-74. DOI: 10.1002/hep.23787. View

Hsu C, Liu C, Liu C, Wang C, Chen C, Lai M . Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009; 104(3):598-604. DOI: 10.1038/ajg.2008.125. View

Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H . Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007; 14(9):600-7. DOI: 10.1111/j.1365-2893.2006.00836.x. View

Prati D, Shiffman M, Diago M, Gane E, Reddy K, Pockros P . Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol. 2006; 44(4):679-85. DOI: 10.1016/j.jhep.2006.01.004. View

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

Kapadia S, Chisari F . Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005; 102(7):2561-6. PMC: 549027. DOI: 10.1073/pnas.0409834102. View

Pawlotsky J, Dahari H, Neumann A, Hezode C, Germanidis G, Lonjon I . Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004; 126(3):703-14. DOI: 10.1053/j.gastro.2003.12.002. View

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

Kim H, Nam C, Jee S, Han K, Oh D, Suh I . Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004; 328(7446):983. PMC: 404493. DOI: 10.1136/bmj.38050.593634.63. View

10.

Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y . Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139(2):499-509. DOI: 10.1053/j.gastro.2010.04.049. View

11.

Hsu C, Liu C, Liu C, Chen C, Lai M, Chen P . Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther. 2009; 14(1):45-54. View

12.

Kao J, Chen D . Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol. 2000; 15 Suppl:E91-6. DOI: 10.1046/j.1440-1746.2000.02108.x. View

13.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

14.

Hsu C, Liu C, Lai M, Chen P, Kao J, Chen D . Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology. 2007; 50(4):310-5. DOI: 10.1159/000105444. View

15.

Dill M, Duong F, Vogt J, Bibert S, Bochud P, Terracciano L . Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2010; 140(3):1021-31. DOI: 10.1053/j.gastro.2010.11.039. View

16.

Fried M . Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl 1):S237-44. DOI: 10.1053/jhep.2002.36810. View

17.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

18.

Ramcharran D, Wahed A, Conjeevaram H, Evans R, Wang T, Belle S . Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010; 52(3):854-63. PMC: 2938827. DOI: 10.1002/hep.23796. View

19.

Urban T, Thompson A, Bradrick S, Fellay J, Schuppan D, Cronin K . IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52(6):1888-96. PMC: 3653303. DOI: 10.1002/hep.23912. View

20.

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View